An open label dose-ranging study in healthy male subjects to investigate the binding potential of JNJ-40411813 to serotonin 2A receptors in the central nervous system.

Completed

• Conditions: mental disorder; psychosis; 10039628

• Registration Number: NL-OMON36262
• Lead Sponsor: Janssen-Cilag

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

Male
Age between 18-45 (inclusive)
BMI between 18 and 30 kg/m^2 (inclusive)

Exclusion Criteria

Clinical significant abnormalities during medical research

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To estimate the plasma concentration associated with 50% 5-HT2A binding.<br /><br>To determine the 5-HT2A binding within the maximal feasible dose range.<br /><br>To investigate if there is a change in plasma concentration-occupancy relation<br /><br>over time.<br /><br>To investigate the safety and tolerability of JNJ-40411813 in healthy male<br /><br>subjects. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>